

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number  
**WO 2004/047756 A2**

(51) International Patent Classification<sup>7</sup>:

**A61K**

7 Hashirion St., Raanana 43266 (IL). **LERNER, David**; 27/4 Yigal St., Ramot 02, Jerusalem 97241 (IL).

(21) International Application Number:

PCT/US2003/037592

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(22) International Filing Date:

20 November 2003 (20.11.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:

10/301,540 21 November 2002 (21.11.2002) US

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


Applicants: Daniella Licht et al.

Serial No.: 10/772,911

Filed: February 5, 2004

**Exhibit 6**

(54) Title: PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES



(57) **Abstract:** The subject invention provides compounds having the structure (I): wherein R<sub>1</sub> is present or absent, and when present is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> aminoalkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl or -(CH<sub>2</sub>)<sub>n</sub>C(=O)(C<sub>6</sub>H<sub>4</sub>)(CH<sub>2</sub>)<sub>n</sub>R<sub>2</sub>; wherein n is an integer from 1-6; wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that x+y<6; at least one of R<sub>1</sub> or R<sub>4</sub> is present; the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and any compound is charged when both R<sub>1</sub> and R<sub>4</sub> are present, or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof, and a method for treating a neurologic disorder or multiple sclerosis by administering a therapeutically effective amount any of the compounds..

present or absent, and when present is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> aminoalkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl or -(CH<sub>2</sub>)<sub>n</sub>C(=O)(C<sub>6</sub>H<sub>4</sub>)(CH<sub>2</sub>)<sub>n</sub>R<sub>2</sub>; wherein n is an integer from 1-6; wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that x+y<6; at least one of R<sub>1</sub> or R<sub>4</sub> is present; the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and any compound is charged when both R<sub>1</sub> and R<sub>4</sub> are present, or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof, and a method for treating a neurologic disorder or multiple sclerosis by administering a therapeutically effective amount any of the compounds..

5

**PROPARGYL-TRIFLUOROMETHOXY-**  
**AMINO-BENZOTHIAZOLE DERIVATIVES**

Throughout this application various publications are referenced in parenthesis. The disclosures of these publications in their entireties are hereby incorporated by 10 reference into this application in order to more fully describe the state of the art to which this invention pertains.

**Background of the Invention**

15 Neurologic disorders are becoming increasingly common in North America. For example, Parkinson's disease is the second most common neurologic disorder, affecting nearly 1 million people in North America. Thus, developing an effective treatment for neurologic disorders has become a high priority in the drug 20 industry.

Neurologic disorders can generally be divided into two groups based on their physiological and pathological characteristics. Parkinson's disease, Alzheimer's disease, Huntington's disease 25 and amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) are all progressive disorders (i.e., their symptoms are not apparent until months or more commonly years after the disease has begun), caused by an initial reduction of neuronal function, followed by a complete loss of function upon 30 neuronal death. In addition, these progressive neurologic disorders are characterized by the presence of protein aggregates that are believed to hamper cellular functions (e.g., neurotransmission), and may ultimately result in cell death (Sasaki et al., *Am. J. Pathol.*, 153:1149-1155 [1998]).

Multiple sclerosis is a disorder of the central nervous system, which is slowly progressive and is characterized by disseminated patches of demyelination in the brain and spinal cord, resulting in multiple and varied neurologic symptoms and 5 signs, usually with remissions and exacerbations. The cause is unknown but an immunologic abnormality is suspected (THE MERCK MANUAL, 17th EDITION, 1999 MERCK & CO.). Several different drug therapies are currently being investigated.


10 While the aforementioned disorders are all slowly progressive, neurological dysfunction can also be caused by a more abrupt event such as an infarction of brain tissue, or stroke. Brain stroke is the third leading cause of death in the developed countries. Survivors often suffer from neurological and motor 15 disabilities. The majority of central nervous system ("CNS") strokes are regarded as localized tissue anemia following obstruction of arterial blood flow which causes oxygen and glucose deprivation. R(+)-N-propargyl-1-aminoindan has been shown to be an effective treatment for stroke and traumatic 20 brain injury (U.S. Patent No. 5,744,500).

A series of propargylamines, including Selegiline and Rasagiline, have been shown to prevent apoptosis in dopamine neurons in Parkinson's models (Naoi, M. et al. *J. Neural Transmission* (2002) 109: 607-721). N-Propargyl-1-Aminoindan 25 has recently been suggested as being useful for treating Parkinson's disease, dementia and depression (U.S. Patent No. 5,453,446). The neuroprotective activity of these molecules is attributed by some to the presence of the propargyl moiety. The mechanism by which the propargyl moiety may confer 30 neuroprotection is not fully understood. However, it is clear that the mechanism involves a complex set of neurochemical events including alterations in Bcl-2, GAPDH, SOD and catalase (Youdim, M.B.H. *Cell. Mol. Neurobiol.* (2001) 21(6): 555-573).

Riluzole (6-trifluoromethoxy-2-amino-benzothiazole) has recently emerged as a pharmacological agent potentially useful to slow down the evolution of amyotrophic lateral sclerosis, a 5 neurologic disorder. (Ben Simon et al., *New Engl. J. Med.*, 330:585-91 (1994)). PCT International Publication No. WO 01/95907 suggests the use of Riluzole for treatment or prevention of the onset of symptoms of multiple sclerosis. PCT International Publication No. WO 00/74676 suggests the use of 10 Riluzole for treatment of multiple sclerosis either alone or in combination with other drugs.

6-trifluoromethoxy-2-amino-benzothiazole, PK 26124, RP 54274, Riluzole, was synthesized for the first time by a Russian 15 group (*J. Gen. Chem. USSR*, 1963, 33, 2240-2246, U. S. Pat. 2,822,359; *Ch.A.*, 52, 8570d 1958) as a part of their investigation on the influence of electronegative substituents at the 6 position of the benzothiazole nucleus on the color of diazastyryl bases.

20



Riluzole

2-Aminobenzothiazoles exist in tautomeric forms (where the proton is shifted between the 2-amino group and the ring 25 nitrogen). When this process is blocked by complete alkylation of the 2-amino group or by alkylation of the ring nitrogen to give for instance 2-imino-3-methylbenzothiazoline, the depressant effect of the 2-aminobenzothiazole is changed to stimulation of the CNS. (Domino, E.F. et al., *J. Pharmacol. Exp. Ther.*, (1952) 105: 486-497) Domino and co-workers have 30 also shown that the azole structure is essential for the

paralyzing effect of the benzazoles, since opening that ring system resulted in convulsing activity. None of the benzazoles had any curare-like action in doses producing paralysis.

5 A group of 6-trifluoromethoxy-2-amino-benzothiazoles bearing a variety of substituents on the amino group was generically disclosed in European Patent No. EP 282 971 and U.S. Patent Nos. 4,826,860, 4,918,090, and 4,971,983, as effective for treating cerebrovascular disorders.


10

U.S. Patent No. 4,535,088 discloses propynylaminothiazole derivatives having anti-fungal and/or anti-microbial activity.

15 The present invention provides novel derivatives of propargyl-trifluoromethoxy-amino-benzothiazole which are effective at treating neurologic disorders, including Parkinson's disease, and multiple sclerosis.

**Summary of the Invention**

The subject invention provides compounds having the structure:



wherein

R<sub>1</sub> is present or absent, and when present is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> aminoalkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl or -(CH<sub>2</sub>)<sub>n</sub>C(=O)(C<sub>6</sub>H<sub>4</sub>)(CH<sub>2</sub>)R<sub>2</sub>;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>4</sub> is present or absent, and when present is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> aminoalkyl, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl or -(CH<sub>2</sub>)<sub>n</sub>C(=O)(C<sub>6</sub>H<sub>4</sub>)(CH<sub>2</sub>)R<sub>2</sub>;

wherein n is an integer from 1-6;

wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that x+y<6;

at least one of R<sub>1</sub> or R<sub>4</sub> is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

any compound is charged when both R<sub>1</sub> and R<sub>4</sub> are present,

or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof.

The subject invention also provides a method for treating a subject afflicted with a neurologic disorder comprising

administering to the subject a therapeutically effective amount of any of the compounds of the invention or pharmaceutically acceptable salts thereof so as to thereby treat the neurologic disorder in the subject.

5

The subject invention also provides a method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of any of the compounds of the invention or 10 pharmaceutically acceptable salts thereof so as to thereby treat multiple sclerosis in the subject.

**Detailed Description of the Figures**

**Figure 1-A** shows the daily EAE GMS for compound 3 (10 mg/kg twice daily).

5           -♦- indicates the control group (PBS);  
          -■- indicates the group under study.

**Figure 1-B** shows the daily EAE GMS for Glatiramer Acetate (75  $\mu$ g/mouse).

10           -♦- indicates the control group (PBS);  
          -■- indicates the group under study.

**Figure 1-C** shows the daily EAE GMS for Glatiramer Acetate (75  $\mu$ g/mouse) + Compound 3 (10 mg/kg twice a day).


15           -♦- indicates the control group (PBS);  
          -■- indicates the group under study.

**Figure 2** shows dose response of EAE MMS (averages from several experiments) for Compound 3  
20           (a) in CSJL/F1 mice  
          (b) in Lewis rats

### Detailed Description of the Invention

The subject invention provides compounds having the structure (Formula I):

5



wherein

10  $R_1$  is present or absent, and when present is H,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkynyl,  $-(CH_2)_yS(CH_2)_xCH_3$ ,  $C_1-C_6$  aminoalkyl,  $C_1-C_6$  hydroxyalkyl or  $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$ ;

$R_2$  is H or  $C_1-C_4$  alkyl;

$R_3$  is H or  $C_1-C_4$  alkyl;

15  $R_4$  is present or absent, and when present is H,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkynyl,  $-(CH_2)_yS(CH_2)_xCH_3$ ,  $C_1-C_6$  aminoalkyl,  $C_1-C_6$  hydroxyalkyl or  $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$ ;

-----wherein  $n$  is an integer from 1-6;

20 wherein  $x$  is 0 or an integer from 1-5 and  $y$  is an integer from 1-5, such that  $x+y < 6$ ;

at least one of  $R_1$  or  $R_4$  is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

25 any compound is charged when both  $R_1$  and  $R_4$  are present,

or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof.


30

In a first embodiment of the above compounds, at least one of R<sub>1</sub> or R<sub>4</sub> is -(CH<sub>2</sub>)<sub>n</sub>C(=O)(C<sub>6</sub>H<sub>4</sub>)(CH<sub>2</sub>)R<sub>2</sub>.

5 In a second embodiment of the above compounds, at least one of R<sub>1</sub> and R<sub>4</sub> is -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>.

In a third embodiment of the above compounds, the subject invention provides compounds having the structure (Formula II):

10



wherein

15 R<sub>1</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>4</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

20 at least one of R<sub>1</sub> or R<sub>4</sub> is present;


the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and

25 any compound is claimed when both R<sub>1</sub> and R<sub>4</sub> are present,


or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof.

In what follows, the phrase "compounds which are represented by Formula II" refers to compounds which are encompassed by the preceding description.

5 In a second embodiment of the compounds represented by Formula II, the compounds have the structure:




In a third embodiment of the compounds have the structure:



10

In a fourth embodiment, the compounds have the structure:



15 In a further embodiment of any of the aforementioned compounds represented by Formula II, at least one of R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl.

20 In another embodiment of any of the aforementioned compounds represented by Formula II, R<sub>1</sub> is H or methyl; R<sub>2</sub> is H or methyl; and R<sub>3</sub> is H or methyl, or a pharmaceutically acceptable salt thereof.

In another embodiment of the third embodiment of the compounds represented by Formula I or the third embodiment of the compounds represented by Formula II, R<sub>1</sub> is absent and R<sub>4</sub> is present.


In a further aspect of the above embodiment, R<sub>1</sub> is absent and R<sub>4</sub> is methyl.

10 In another embodiment of any of the aforementioned compounds represented by Formula II, the chiral carbon is in the R configuration.

15 In another embodiment of any of the aforementioned compounds represented by Formula II, the chiral carbon is in the S configuration.


20 In a further embodiment the subject invention provides the pharmaceutically acceptable salt of any of the aforementioned compounds, wherein the salt is the chloride, mesylate, maleate, fumarate, tartarate, hydrochloride, hydrobromide, mesylate, p-toluenesulfonate, benzoate, acetate, phosphate or sulfate salt.

In one embodiment of the first embodiment of the compounds represented by Formula I, the compound has the structure:




5

In one embodiment of the compounds represented by Formula I, the compound has the structure:




10

In one embodiment of the second embodiment of the compounds represented by Formula I, the compound has the structure:




In another embodiment of the second embodiment of the compounds represented by Formula I, the compound has the structure:



5

Compound 15


In one embodiment of the compounds represented by Formula I, the compound has the structure:



10---


Compound 14

In another embodiment of the first embodiment of the compounds represented by Formula I, the compound has the structure:



Compound 13

5 In another embodiment of the compounds represented by the fourth embodiment of compounds represented by Formula II, the compound has the structure:




Compound 3

10

In a further embodiment, the subject invention provides the hydrochloride salt of the above compound.


15 In another embodiment of the compounds represented by the fourth embodiment of compounds represented by Formula II, the compound has the structure:



Compound 4

In a further embodiment, the subject invention provides the hydrochloride salt of the above compound.


In another embodiment of the compounds represented by the  
5 fourth embodiment of compounds represented by Formula II, the  
compound has the structure:



### Compound 5

10 In a further embodiment, the subject invention provides the hydrochloride salt of the above compound.

In another embodiment of the compounds represented by the fourth embodiment of compounds represented by Formula II, the 15 compound has the structure:




### Compound 6

In a further embodiment, the subject invention provides the hydrochloride salt of the above compound.

In another embodiment of the compounds represented by the second embodiment of compounds represented by Formula II, the compound has the structure:

5




Compound 3b

In a further embodiment, the subject invention provides the hydrochloride salt of the above compound.

10

In another embodiment of the compounds represented by the third embodiment of compounds represented by Formula II, the compound has the structure:

15




Compound 10

In a further embodiment, the subject invention provides the hydrochloride salt of the above compound.

20


In another embodiment of the compounds represented by Formula II, the compound has the structure:



Compound 16

5

In another embodiment of the compounds represented by Formula II, the compound has the structure:



Compound 12

10

The subject invention also provides a method for treating a subject afflicted with a neurologic disorder comprising administering to the subject a therapeutically effective amount of any of the aforementioned compounds represented by Formula I or a pharmaceutically acceptable salt thereof, so as to thereby treat the neurologic disorder in the subject.

In one embodiment of the above method, the disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.

In a further embodiment of the above method, the therapeutically effective amount is from about 1 to about 1000 mg/day.

5 The subject invention also provides a method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of any of the aforementioned compounds represented by Formula I or a pharmaceutically acceptable salt thereof so as  
10 to thereby treat multiple sclerosis in the subject.

In one embodiment, the above method further comprises administering to the subject a therapeutically effective amount of levodopa, glatiramer acetate, interferon beta-1b,  
15 interferon beta-1a, steroids or Mitoxantrone (Novantrone).

In another embodiment of the above method, the therapeutically effective amount is from about 1 to about 1000 mg/day.

20 In one embodiment of either of the above methods the therapeutically effective amount of the compound is administered by injection, systemically, orally or nasally.

The subject invention also provides the use of any of the  
25 aforementioned compounds for manufacturing a medicament useful for treating a neurologic disorder in a subject.

In one embodiment of the above use, the neurologic disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral  
30 sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.

The subject invention also provides the use of any of the aforementioned compounds for manufacturing a medicament useful for treating multiple sclerosis in a subject.

5 In one embodiment of the above use, the medicament further comprises levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone (Novantrone).

As noted above, the compounds of this invention may be used  
10 therapeutically in addition to currently available treatments for neurologic disorders. For instance, the compounds of the invention may be used in addition to levodopa therapy for Parkinson's disease or in addition to glatiramer acetate (the drug substance of Copaxone), interferon beta-1b, interferon  
15 beta-1a, steroids or Mitoxantrone (Novantrone).

The subject invention also provides the use of any of the aforementioned compounds for manufacturing a medicament in a package having instructions for administration of the  
20 medicament to treat a neurologic disorder in a subject.

The subject invention also provides a method for destroying or inhibiting the proliferation of microbes or fungus which comprises contacting the microbes or fungus with a composition  
25 comprising any of the aforementioned compounds and an acceptable carrier.

The subject invention also provides a pharmaceutical composition comprising any of the aforementioned compounds and  
30 a pharmaceutically acceptable carrier.

In one embodiment the pharmaceutical composition further comprises a therapeutically effective amount of levodopa,

glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone (Novantrone).


In one embodiment the pharmaceutical composition further 5 comprises a therapeutically effective amount of glatiramer acetate.

The subject invention also provides a process for the manufacture of the above pharmaceutical composition comprising 10 admixing any of the aforementioned compounds with a pharmaceutically acceptable carrier.


The subject invention also provides a packaged pharmaceutical composition for treating a neurologic disorder in a subject 15 comprising: (a) any of the aforementioned pharmaceutical compositions; and (b) instructions for using the composition for treating the neurologic disorder in the subject.

The subject invention also provides a process of manufacturing 20 compound of Structure II, comprising the steps of:


— (a) reacting



25 under suitable conditions with an amine exchanging agent in the presence of solvent to provide:




(b) treating **2** with a chlorinating agent to provide




3

5 (c) reacting **3** with



10 to provide



wherein

15 R<sub>1</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;


R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; and

20 (d) optionally alkylating the product of step (c), wherein R<sub>1</sub> is H, to provide the compound.

In one embodiment, the above process further comprises reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are


each H, with 2-bromo-4'-methylacetophenone in a polar solvent in the presence of a base to produce a compound having the structure:



5

In one embodiment the polar solvent is acetonitrile and the base is potassium carbonate.

In a further embodiment of the above process for manufacturing 10 compounds of structure II, the process further comprises reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each H, with propargyl bromide in a polar solvent in the presence of a base to produce a compound having the structure:




15

In one embodiment, the polar solvent is acetonitrile and the base is potassium carbonate.

In a further embodiment of the above process for manufacturing 20 compounds of structure II, the process further comprises reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each H, with 2-chloroethyl methylsulfide in a polar solvent in

the presence of a base, to produce a compound having the structure:



5 In one embodiment, the polar solvent is acetonitrile and the base is potassium carbonate.

In one embodiment of the above process for manufacturing compounds of structure II, the amine exchanging agent is a 10 mixture of aqueous  $\text{NH}_2\text{NH}_2$  and hydrazinium sulfate in ethylene glycol.

In another embodiment of the above process, the chlorinating agent is  $\text{SOCl}_2$ .


15

In another embodiment of the above process,  $\text{R}_1$  is  $\text{C}_1\text{-C}_4$  alkyl and  $\text{R}_2$  and  $\text{R}_3$  are H.

In a further embodiment of the above process for manufacturing 20 compounds of structure II, the alkylating agent in step (d) is methyliodide or dimethyl sulfate.

The subject invention also provides a process of manufacturing a compound having the structure:

25




wherein

R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; and

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl,

5 comprising reacting a compound having the structure:




with R<sub>1</sub>X in a polar solvent in the presence of a base, wherein X is a halogen atom, to produce the compound.

10

In one embodiment of the above process, the polar solvent is acetonitrile and the base is potassium carbonate.

The subject invention also provides a process of manufacturing  
15 a compound having the structure:




wherein

20 R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl; and


R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl,

comprising,


25 a) reacting



under suitable conditions with a methylating agent, in the presence or absence of solvent to provide:




5 b) reacting the product of step a) with



in the presence of p-toluenesulfonic acid to provide the compound.

10

In one embodiment of the above process, the product of step (b) is further alkylated with an alkylating agent to provide a compound having the structure:




15

In an additional embodiment of the above process, the methylating agent in step (a) is methyl iodide or dimethyl sulfate.

20


In a further embodiment of the above process, the methylating agent is methyliodide.

The subject invention further provides a process of  
5 manufacturing compound 14 comprising reacting a compound having the structure:




with propargylamine and p-TsOH in toluene to produce the  
10 compound.

The subject invention further provides a process of manufacturing compound 15 comprising reacting a compound having the structure:




15 with propargylamine and p-TsOH in toluene to produce the compound.

The subject invention further provides a process of  
20 manufacturing compound 9 comprising reacting a compound having the structure:



with



in a polar solvent to produce the compound.

5

In one embodiment of the above process, the polar solvent is acetonitrile.

In the above embodiments, when both  $R_1$  and  $R_4$  are alkyl the 10 compound is positively charged and is present as a quaternary ammonium salt.

Those skilled in the art will readily expect all of the disclosed compounds to have biological activity similar to the 15 tested compounds. In particular, compounds with both small groups, such as H and methyl, and bulky groups, such as p-tolyl-ethanone, in the  $R_4$  position have biological activity in the described results. Consequently, compounds with the described intermediate sized groups at the  $R_4$  position are 20 reasonably expected to have biological activity. Compounds with small groups, such as methyl, in the  $R_1$  position have biological activity. Compounds with bulky groups, such as p-tolyl-ethanone, in the  $R_1$  position have biological activity. Consequently, compounds with the described intermediate sized 25 groups at the  $R_1$  position are reasonably expected to have

biological activity. Compounds with small groups, such as H, in the R<sub>2</sub> or R<sub>3</sub> positions have biological activity. Consequently, compounds with the described C<sub>1</sub>-C<sub>4</sub> alkyl at the R<sub>2</sub> or R<sub>3</sub> position are reasonably expected to have biological 5 activity.

Those skilled in the art will be familiar with the fact that some compounds of the formula (I) can exist as tautomers. The compounds of the formula (I) are therefore also to be 10 understood as meaning, hereinabove and hereinbelow, the relevant tautomers, even when the latter are not mentioned specifically in each individual case. This invention also relates to the use of all such tautomers and mixtures thereof.

15 The subject invention further provides any of the aforementioned compounds for use as antimicrobial and/or antifungal agents.

The invention further contemplates the use of prodrugs which 20 are converted *in vivo* to the therapeutic compounds of the invention (see, e.g., R.B. Silverman, 1992, "The Organic Chemistry of Drug Design and Drug Action", Academic Press, Chapter 8, the entire contents of which are hereby incorporated by reference). Such prodrugs can be used to 25 alter the biodistribution (e.g., to allow compounds which would not typically enter the reactive site of the protease) or the pharmacokinetics of the therapeutic compound.

As set out above, certain embodiments of the present compounds 30 can contain a basic functional group, such as amino or alkylamino, and are thus capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic, inorganic and organic acid

addition salts of compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in 5 its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, 10 citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977) "Pharmaceutical Salts", *J. Pharm. Sci.* 66:1-19).

15 The term "pharmaceutically acceptable salts" as used herein also includes a quaternary ammonium salt.

It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms and thus 20 occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in this invention. Each stereogenic carbon may be of the R or S configuration. It is to be understood accordingly that the 25 isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis.

30 When the compounds of the present invention are administered as pharmaceuticals, to humans and mammals, they can be given *per se* or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active

ingredient in combination with a pharmaceutically acceptable carrier.

The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it can performs its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.

Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring

and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include:  
5 water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-  
10 tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

Formulations of the present invention include those suitable for oral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to 25 about 30 per cent.

Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or 30 more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Formulations of the invention suitable for oral administration may be in the form of capsules, pills, tablets, powders, granules, or as a solution or a suspension in an aqueous or 5 non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present 10 invention as an active ingredient.

In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more 15 pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl 20 pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary 25 ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring 30 agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules

using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally 5 with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), 10 surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the 15 pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide 20 slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-25 retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that 30 they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-

encapsulated form, if appropriate, with one or more of the above-described excipients.

Liquid dosage forms for oral administration of the compounds 5 of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert dilutents commonly used in the art, such as, for example, water or other solvents, 10 solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, 15 tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert dilutents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and 20 suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl 25 alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Pharmaceutical compositions of this invention suitable for 30 parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions

or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

5

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,

transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

5 The phrases "systemic administration," "administered systematically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's  
10 system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so  
15 as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

20 The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular  
25 compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

30 A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds

of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

5

In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the 10 lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

15

If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.

20

It is noted that the compounds of the invention can prevent neuronal death and improve the outcome in various models 25 resembling human degenerative disorders.

The phrase "neurologic disorder" as used herein refers to a disorder whose adverse affects are localized in the nervous 30 system.

The term "neurotrauma" as used herein, refers to damage to the central or peripheral nervous system caused by a traumatic

event, such as head trauma, spinal trauma, neurotoxic injury, stroke, ischemia, hypoxia, or anoxia.

The term "stroke" or "ischemic stroke" as used herein means a  
5 brain infarct manifested by neurologic deficits. "Stroke" may refer to a "stroke in evolution" in which the infarction is still enlarging or a "completed stroke" in which the infarction size is no longer growing. (THE MERCK MANUAL, 17th EDITION, 1999 MERCK & CO.)

10

The phrase "treatment of stroke" as used herein is meant to include the treatment of the brain infarction per se or the treatment of the symptoms caused by the brain infarction. Such symptoms may include neurological deficits, cognitive  
15 disturbances, brain edema, decreased cerebral blood flow, catecholamine fluctuations, or neurological or motor disabilities.

The invention is further illustrated by the following examples  
20 which in no way should be construed as being further limiting. The contents of all references, pending patent applications and published patent applications, cited throughout this application, including those referenced in the background section, are hereby incorporated by reference. It should be  
25 understood that the models used throughout the examples are accepted models and that the demonstration of efficacy in these models is predictive of efficacy in humans.


This invention will be better understood from the Experimental  
30 Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter.

Experimental Details

A synthesis scheme for the preparation of a group of compounds of the invention is outlined below in Scheme I.

5

Scheme I



Benzothiazoles **Ia** and **Ib** were prepared by converting 6-trifluoromethoxy 2-amino benzothiazole to the corresponding 2-hydrazino analogue by direct exchange amination (C. J. Barnett and J. C. Smirz, *Organic. Prep. Proc. Int.* 6(4), 1974, 179-182) using a mixture of aqueous hydrazine and hydrazinium sulfate in ethylene glycol, followed by substituting the 2-hydrazino group with a chlorine atom by reacting **1** with  $\text{SOCl}_2$ , to give **2** (Barry A. Dreikorn and Paul Unger, *J. Heterocyclic Chem.*, 26, 1989, 1735-1737), and finally reacting the latter with substituted propargylamines, to afford the compounds of formula **Ia** and **Ib**. Compounds **Ib** were also prepared by reacting **Ia** with alkylating agents  $\text{R}_1\text{X}$  in a polar solvent, e.g. acetonitrile, in the presence of a base, e.g. potassium carbonate, at ambient temperature. 2-Imino derivatives **Ic** were prepared by regioselective alkylation of 6-trifluoromethoxy-2-amino-benzothiazole with alkylating agents  $\text{R}_4\text{X}$  to give 3-alkyl-2-imino-6-trifluoromethoxy-benzothiazoline **1a** (Patrick Jimonet et al., *J. Med. Chem.* 1999, 42, 2828-2843) in high yield, followed by propargylation of the 2-imino moiety by reacting **1a** with propargylamines in the presence of p-TsOH (CH patent 667091 A5) either in toluene as the reaction solvent or neat with excess amine. Compounds **Ic** were also prepared as their acid addition salts by alkylation of **Ia** by using an excess of an alkylating agent  $\text{R}_4\text{X}$ , in a suitable solvent, e.g. methyl ethyl ketone (A. R. Katritzky et al. *J. Chem. Soc. Perkin Trans. I*, 1987, 2539-2541) or acetonitrile and concentrating the reaction mixture, treating the residue with toluene and filtering the salt. Alkylating compounds **Ic** (as their free base) with an excess of alkylating agents  $\text{R}_1\text{X}$  provided the quaternary 3-alkyl-benzothiazolium salt **Id**, isolated by filtration.

**Example 1: (6-Trifluoromethoxy-benzothiazol-2-yl)-hydrazine 1**

A suspension of 6-trifluoromethoxy-2-amino-benzothiazole (crude, 1 g, 4.27 mmol), hydrazinium sulfate ( $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{SO}_4$ , 0.85 g, 6.53 mmol) and hydrazine hydrate (~ 82% aqueous solution, 5 2.7 ml, ~ 45 mmol) in ethylene glycol (10 ml) was heated with stirring under  $\text{N}_2$  atm. at 140 °C for 2.5 h. When the solution was cooled to rt a white solid precipitated, water (10 ml) was added to complete precipitation, the product filtered, washed with water and vacuum dried to give 1 (0.7 g, 65%) as a white 10 powder.  $^1\text{H-NMR}$  ( $\text{CD}_3\text{CN}$ )  $\delta$  7.70 (br s, 1 H, NH), 7.63 (dq, 1 H, J = 2, 1 Hz, H-7), 7.41 (d, 1 H, J = 9 Hz, H-4), 7.18 (ddq, 1 H, J = 9, 2, 1 Hz, H-5), 4.50 (br s, 2 H,  $\text{NH}_2$ );  $^{13}\text{C}$  ( $\text{CD}_3\text{CN}$ )  $\delta$  115.81, 120.35, 120.58 (3 x CH, C-4, C-5, C-7), 120.93 ( $\text{CF}_3\text{O}$ ), 133.01, 143.89, 153.47 (3 x C, C-3a, C-7a, C-6), 176.27 (C-2); 15 MS (CI) ( $\text{NH}_3$ ) m/z (234,  $\text{MH}^+ - \text{NH}_3 + \text{H}^+$ ), 250 ( $\text{MH}^+$ ).

**Example 2: 2-Chloro-6-trifluoromethoxy-benzothiazole 2**

Into  $\text{SOCl}_2$  (6 ml, 82 mmol) preheated to 65 °C was added 1 (0.95 g, 3.81 mmol) slowly (within an hour) and the solution was 20 stirred an additional 1 h at 60 °C.  $\text{SOCl}_2$  was evaporated, the residue was dissolved in  $\text{CH}_2\text{Cl}_2$  and solvent evaporated and this treatment of dissolving and evaporating was repeated 4-5 times until almost all  $\text{SOCl}_2$  was removed to give crude 2 ready for use in the next step without purification.  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  25 7.95 (d, 1 H, J = 9 Hz, H-4), 7.66 (dq, 1 H, J = 2, 1 Hz H-7), 7.36 (ddq, 1 H, J = 9, 2, 1 Hz, H-5);  $^{13}\text{C}$  ( $\text{CDCl}_3$ )  $\delta$  113.79 (CH, Ar), 120.46 ( $\text{CF}_3\text{O}$ ), 120.68, 123.88 (2 x CH, Ar), 136.90, 146.91, 149.52 (3 x C, C-3a, C-7a, C-6), 154.22 (C-2); MS (CI) ( $\text{NH}_3$ ) m/z (254,  $\text{M}^+ - \text{NH}_4^+$ ).

30

**Example 3: Methyl-prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine 3**

Crude 2 (~2 mmol) was dissolved in N-methyl-propargylamine (~2 ml, 3.5 eq) and the dark solution was stirred at rt overnight

after which a brown solid was obtained and purified by chromatography to give 3. m.p. (for free base) = 86-87°C; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 7.56 (d, 1H, J=10 Hz, H-4), 7.49 (dd, 1H, J=2, 1 Hz, H-7), 7.18 (ddq, 1H, J=10, 2, 1 Hz, H-5), 4.4 (d, 2H, J=2.5 Hz, CH<sub>2</sub>N), 3.22 (s, 3H, NMe), 2.31 (t, 1H, J=2.5 Hz, PgCH); <sup>13</sup>C (for free base, CDCl<sub>3</sub>) δ 168.61 (C-2), 151.36, 143.38, 131.76 (3 x C, C-3a, C-7a, C-6), 120.6 (CF<sub>3</sub>O), 119.78, 119.54, 113.89 (3 x CH, Ar), 80.21, 73.11 (CH<sub>2</sub>CC), 41.49 (NCH<sub>2</sub>), 37.82 (NMe); MS (CI) (NH<sub>3</sub>) m/z (287, MH<sup>+</sup>); Anal. (calcd. For C<sub>12</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>OS) C 50.35, H 3.17, N 9.79, S 11.20, found C 50.62, H 3.23, N 9.60, S 11.44.

**Example 3a:** Methyl-prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine.HCl salt 3a

Free base 3 was dissolved in HCl/EtOH solution, stirred for 0.5 h and the product was precipitated by addition of Et<sub>2</sub>O, filtered, washed with Et<sub>2</sub>O and dried to give 1.15 g (65%) of 3a. m.p.= 160-162.5°C; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ 7.98 (dd, 1H, J = 2 Hz, H-7), 7.58 (d, 1H, J = 10 Hz, H-4), 7.32 (ddq, 1H, J = 10, 2, 1 Hz, H-5), 4.44 (d, 2H, J = 2.5 Hz, CH<sub>2</sub>N), 3.39 (t, 1H, J = 2.5 Hz, PgCH), 3.18 (s, 3H, NMe); <sup>13</sup>C (DMSO-d<sub>6</sub>) δ 169.09 (C-2), 151.83, 142.66, 132.14 (3 x C, C-3a, C-7a, C-6), 120.6 (CF<sub>3</sub>O), 119.91, 119.43, 115.06 (3 x CH, Ar), 78.69, 75.65 (CH<sub>2</sub>CC), 41.42 (NCH<sub>2</sub>), 37.95 (NMe); MS (CI) (NH<sub>3</sub>) m/z (287, MH<sup>+</sup>).

25

**Example 3b:** Methyl-prop-2-ynyl-(4-trifluoromethoxy-benzothiazol-2-yl)-amine 3b

This compound can be prepared by the same synthetic procedure described for methyl-prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine 3, starting from 4-(trifluoromethoxy)-2-benzothiazolamine, reacting it with hydrazinium sulfate and hydrazine hydrate in ethylene glycol, followed by reaction with SOCl<sub>2</sub> and reacting the intermediate with N-methyl-propargylamine.

**Example 4:** Prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine **4**

Propargylamine (0.66 ml, 9.6 mmol, ~3.5 eq) was added into **2** (obtained from 0.67 g, 2.7 mmol of **1** reacted with 6 ml  $\text{SOCl}_2$ ) 5 and the dark solution obtained was stirred at rt overnight, and then loaded on a chromatography column which resulted in 0.27 g (37%) of **4** as a gray powder. m.p.= 138-140°C;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  7.59 (d, 1H,  $J=10.5$  Hz, H-4), 7.49 (dq, 1H,  $J=2$ , 1 Hz H-7), 7.21 (ddq, 1H,  $J=10.5$ , 2, 1 Hz, H-5), 4.28 (d, 2H,  $J=2.5$  10 Hz,  $\text{CH}_2\text{N}$ ), 2.35 (t, 1H,  $J=2.5$  Hz, CCH);  $^{13}\text{C}(\text{CDCl}_3)$   $\delta$  167.08 (C-2), 148.70, 144.30, 130.32 (3 x C, C-3a, C-7a, C-6), 120.49 ( $\text{CF}_3\text{O}$ ), 120.20, 119.25, 114.29 (3 CH, Ar), 78.19, 73.17 ( $\text{CH}_2\text{CC}$ ), 34.69 (NCH<sub>2</sub>); MS(CI) (NH<sub>3</sub>)m/z (273,  $\text{MH}^+$ ).

15 **Example 4a:** Prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine.HCl salt **4a**

0.245 g of **4** were dissolved in isopropanol and  $\text{Et}_2\text{O}$ .  $\text{EtOH}/\text{HCl}$  was added until pH=1. After a few minutes of stirring at rt the mixture was evaporated to dryness and the residue dried in 20 vacuum overnight to give the HCl salt of **4**. m.p.= 180-181°C;  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  7.95 (d, 1H,  $J=2$  Hz, H-7), 7.60 (d, 1H,  $J=10$  Hz, H-4), 7.33 (dd, 1H,  $J=10$ , 2 Hz, H-5), 4.35 (d, 2H,  $J=2$  Hz,  $\text{CH}_2\text{N}$ ), 3.37 (t, 1H,  $J=2$  Hz, PgCH); MS(CI) (NH<sub>3</sub>)m/z (273,  $\text{MH}^+$ ); Anal. (calcd. for  $\text{C}_{11}\text{H}_7\text{F}_3\text{N}_2\text{OS} \cdot \text{HCl}$ ) C 42.80, H 2.61, N 9.07, S 25 10.39, Cl 11.48, found C 42.86, H 2.74, N 9.03, S 10.77, Cl 11.30.

**Example 5:** But-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine **5**

30 Compound **5** was obtained by reacting **2** (0.91 g, 3.60 mmol) with but-2-ynylamine (0.93 g, 13.38 mmol, 3.7 eq). Chromatography of the crude product (silica gel, hexane then 10%  $\text{EtOAc}/\text{hexane}$  (200 ml) and finally 20%  $\text{EtOAc}/\text{hexane}$ ) gave 0.5 g (65%) of a white solid.  $^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  8.47 (t, 1H,  $J=5$  Hz, NH), 7.82

(dd, 1H,  $J = 2$ , 1 Hz, H-7), 7.48 (d, 1H,  $J = 9$  Hz H-4), 7.21 (ddq, 1H,  $J=9$ , 2, 1 Hz, H-5), 4.15 (dq, 2H,  $J=5$ , 2 Hz,  $\text{CH}_2\text{N}$ ), 1.80 (t, 3H,  $J=2$  Hz, CCMe);  $^{13}\text{C}$  (DMSO- $d_6$ )  $\delta$  166.77 (C-2), 151.38, 142.34, 131.61 (3 x C, C-3a, C-7a, C-6), 119.11, 5 118.59, 114.58 (3 x CH, Ar), 78.96, 75.83 ( $\text{CH}_2\text{CC}$ ), 33.20 (NCH<sub>2</sub>), 3.08 (CCMe).

**Example 5a:** But-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine.HCl salt **5a**

10 0.255 g of **5** were converted to the HCl salt using HCl/EtOH as described for **3a**.  $^1\text{H}$ -NMR (DMSO- $d_6$ )  $\delta$  9.75 and 9.07 (two br s, 2 x NH), 7.94 (br s, 1H, H-7), 7.59 (br d, 1H,  $J=9$  Hz, H-4), 7.33 (br d, 1H,  $J=9$  Hz, H-5), 4.30 (br s, 2H,  $\text{CH}_2\text{N}$ ), 1.83 (br s, 3H,  $J=2$  Hz, CCMe);  $^{13}\text{C}$  (DMSO- $d_6$ )  $\delta$  167.19 (C-2), 146.13, 15 143.18, 129.35 (3 x C, C-3a, C-7a, C-6), 120.0 ( $\text{CF}_3\text{O}$ ), 119.88, 117.36, 115.39 (3 x CH, Ar), 80.06, 74.60 ( $\text{CH}_2\text{CC}$ ), 34.05 (NCH<sub>2</sub>), 3.11 (CCMe); HRMS(FAB+) 287.0258 (MH<sup>+</sup>, 100), 218.1281 (MH<sup>+</sup>-C<sub>4</sub>H<sub>5</sub>NH<sub>2</sub>, 15).

20 **Example 6:** Methyl-(1-methyl-prop-2-ynyl)-(6-trifluoromethoxy-benzothiazol-2-yl)-amine **6**

Compound **6** was obtained by reacting **2** (6.82 g, 27 mmol) with N-Me-3-butyn-2-amine (11.0 g, 132.3 mmol, ~5 eq). Flash chromatography column of the crude product (silica gel, 10% 25 EtOAc/hexane) gave 4.92 g (60.7%) of a thick and almost transparent oil which solidified when placed in freezer. m.p.=42-43°C;  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ )  $\delta$  7.52 (d, 1H,  $J=9$  Hz, H-4), 7.48 (dd, 1H,  $J=2$ , 0.5 Hz, H-7), 7.16 (ddq, 1H,  $J=9$ , 2, 0.5 Hz, H-5), 5.42 (dq, 1H,  $J=7$ , 2 Hz, MeCHNMe), 3.13 (s, 3H, NMe), 2.38 30 (d, 1H,  $J=2$  Hz, CCH), 1.51 (d, 3H,  $J=7$  Hz, MeCH);  $^{13}\text{C}$  ( $\text{CDCl}_3$ )  $\delta$  168.41 (C-2), 151.43, 143.36, 131.33 (3 x C, C-3a, C-7a, C-6), 120.6 ( $\text{CF}_3\text{O}$ ), 119.76, 119.30, 113.86 (3 x CH, Ar), 81.64, 72.70 ( $\text{CHCC}$ ), 47.08 (MeCHNMe), 33.12 (NMe), 19.29 (CHMe); HRMS(FAB+) 301.1118 (MH<sup>+</sup>, 100), 285.0972 (M-Me, 68); Anal.

(calcd. for  $C_{13}H_{11}N_2OSF_3$ ) C 51.99, H 3.69, N 9.33, S 10.68,  
found C 52.07, H 3.83, N 9.26, S 10.67.

**Example 7:** Di-prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine **7**

Into a solution of prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine (the compound of Ex. 4, 1.5 g, 5.5 mmol) in acetonitrile (40 ml) were added  $K_2CO_3$  (0.78 g, 5.6 mmol) and propargyl bromide (0.68 g, 0.43 ml, 5.7 mmol), and 10 the heterogeneous mixture was stirred at rt for 4 days. The solid was filtered off and the filtrate evaporated to give a yellow solid which was purified by chromatography (hexane/EtOAC) to give **7** as a white solid (0.62 g, 36%).

$^1H$  NMR ( $CDCl_3$ )  $\delta$  7.58 (d, 1H,  $J$  = 9 Hz, H-4), 7.50 (d, 1H,  $J$  = 1.5 Hz, H-7), 7.18 (dd, 1H,  $J$  = 9, 1.5 Hz, H-5), 4.45 (d, 4H,  $J$  = 2 Hz,  $NCH_2$ ), 2.34 (t, 2H,  $J$  = 2 Hz, CCH).

$^{13}C$  NMR  $\delta$ : 167.56 (C-2), 150.99, 143.93, 132.02 (C-3a, C-7a, C-6), 120.2 ( $CF_3O$ ), 120.16, 119.92, 113.99 (3 CH, Ar), 77.12, 73.68 ( $CH_2CC$ ), 39.33 ( $NCH_2$ ).

MS (DCI,  $CH_4$ ) m/z 310 (M), 271 (M- $CH_2CC$ ).

**Example 8:** (2-Methylsulfanyl-ethyl)-prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine **8**

The title compound was prepared by the procedure described in Ex. 7: prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine (the compound of Ex. 4, 1.35 g, 4.96 mmol) was reacted with 2-chloroethyl methylsulfide (0.49 ml, 4.9 mmol) to give **8** as a white solid (0.61 g, 36%).

$^1H$  NMR ( $CDCl_3$ )  $\delta$  : 7.55 (d, 1H,  $J$  = 9 Hz, H-4), 7.48 (dq, 1H,  $J$  = 2, 1 Hz, H-7), 7.17 (ddq, 1H,  $J$  = 9, 2, 1 Hz, H-5), 4.44 (d, 2H,  $J$  = 2 Hz,  $NCH_2CC$ ), 3.83 (t, 2H,  $J$  = 7 Hz,  $NCH_2CH_2S$ ), 2.89 (t, 2H,  $J$  = 7 Hz,  $NCH_2CH_2S$ ), 2.34 (t, 1H,  $J$  = 2 Hz, CCH), 2.21 (s, 3H, SMe).

<sup>13</sup>C NMR δ: 167.57 (C-2), 151.09, 143.65, 131.45 (C-3a, C-7a, C-6), 120.2 (CF<sub>3</sub>O), 119.89, 119.67, 113.94 (3 CH, Ar), 77.80, 73.46 (CH<sub>2</sub>CC), 50.68 (NCH<sub>2</sub>CH<sub>2</sub>S), 40.38 (NCH<sub>2</sub>CC)), 31.39 (NCH<sub>2</sub>CH<sub>2</sub>S), 15.71 (SMe).

5 MS (DCI) (CH<sub>4</sub>) m/z 346 (M), 300 (M-SMe), 285 (M-CH<sub>2</sub>SMe) 272 (M-CH<sub>2</sub>CH<sub>2</sub>SMe).

**Example 9: 2-[Prop-2-ynyl-(6-trifluoromethoxy-benzothiazole-2-yl)-amino]-1-p-tolyl-ethanone 9**

10 The title compound was prepared by the procedure described in Ex. 7: prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine (the compound of Ex. 4, 5.0 g, 18.3 mmol) was reacted with 2-bromo-4'-methylacetophenone (3.9 g, 18.3 mmol) to give 9 as a white solid (3 g, 40%).

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.91 (d, 2H, J = 8 Hz, COAr), 7.50 (d, 1H, J = 9 Hz, H-4), 7.45 (d, 1H, J = 2 Hz, H-7), 7.29 (d, 2H, J = 8 Hz, COAr), 7.14 (ddq, 1H, J = 9, 2, 1 Hz, H-5), 5.17 (s, 2H, CH<sub>2</sub>CO), 4.47 (d, 2H, J = 2 Hz, NCH<sub>2</sub>CC), 2.43 (s, 3H, Ar-CH<sub>3</sub>), 2.36 (t, 1H, J = 2 Hz, CCH).

20 <sup>13</sup>C NMR δ: 193.20 (CO), 168.21 (C-2), 151.15, 145.01, 143.60, 132.32, 131.81 (5 x C, Ar), 129.56, 128.07 (4 x CH MeC<sub>6</sub>H<sub>4</sub>), 120.2 (CF<sub>3</sub>O), 119.77, 113.90 (2 CH, Ar), 77.42, 74.20 (CH<sub>2</sub>CC), 54.89 (NCH<sub>2</sub>CO), 41.15 (NCH<sub>2</sub>), 21.74 (MeC<sub>6</sub>H<sub>4</sub>).

MS (TOF, ES<sup>+</sup>): 405 (MH<sup>+</sup>).

25

**Example 10: (3-Methyl-6-trifluoromethoxy-3H-benzothiazol-2-ylidene)-prop-2-ynyl-amine 10**

2-Imino-3-methyl-6-trifluoromethoxybenzothiazoline (HI salt, 3.26 g, 8.66 mmol) was suspended in toluene (~70 ml) and 30 propargylamine (13 ml, 0.2 mole) and p-TsOH (0.54 g, 2.88 mmol) were added and the mixture stirred at 125°C overnight. Toluene was evaporated and the residue purified on chromatography column (silica gel, hexane, 5% EtOAc/hexane and finally 10% EtOAc/hexane) to give 1.75 g of a white solid.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 7.26 (dq, 1H, J = 2, 1 Hz, H-7), 7.14 (ddq, 1 H, J = 8, 2, 1 Hz, H-5), 6.86 (d, 1 H, J = 8 Hz, H-4), 4.02 (d, 2H, J = 2 Hz, CH<sub>2</sub>N), 3.46 (s, 3 H, NMe), 2.28 (t, 1 H, J = 2 Hz, PgCH); <sup>13</sup>C 158.64 (C-2), 143.20, 139.65, 118.80 (3 x C, 5 C-3a, C-7a, C-6), 122.7 (CF<sub>3</sub>O), 119.81, 115.71, 108.88 (3 x CH, Ar), 80.69, 70.98 (CH<sub>2</sub>CC), 42.20 (NCH<sub>2</sub>), 30.49 (NMe); MS (DCI) (CH<sub>4</sub>) m/z (285, M-H<sup>+</sup>), (271, M-CH<sub>3</sub>).

**Example 11:** (3-Methyl-6-trifluoromethoxy-3H-benzothiazol-2-ylidene)-prop-2-ynyl-amine. HI salt **11**

Prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine (the compound of example 4, 0.3 g, 1.1 mmole) was dissolved in methyl ethyl ketone, (3 ml) and excess MeI (2 ml) was added. The reaction mixture was refluxed for 4.5 h and then an additional amount of MeI (1-2 ml) was added and the reaction mixture was refluxed over night. The mixture was concentrated, toluene was added and the white precipitate obtained, filtered, washed extensively with toluene and dried in vacuum to give 0.285 g (63%) of **11** as a white solid. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 7.66 (dq, 1H, J = 2, 1 Hz, H-7), 7.57 (d, 1H, J = 9 Hz, H-4), 7.50 (ddq, 1H, J = 9, 2, 1 Hz, H-4), 4.50 (d, 2H, J = 2 Hz, CH<sub>2</sub>N), 4.25 (s, 3 H, NMe); 2.49 (t, 1H, J = 2 Hz, PgCH); <sup>13</sup>C (DMSO<sub>d</sub><sub>6</sub>) 168.24 (C-2), 144.57, 138.61, 118.31 (3 x C, C-3a, C-7a, C-6), 122.58 (CF<sub>3</sub>O), 121.59, 116.98, 114.74 (3 x CH, Ar), 77.32, 76.46 (CH<sub>2</sub>CC), 36.26 (NCH<sub>2</sub>), 33.11 (NMe); TOF MS ES m/z (287, MH<sup>+</sup>).

**Example 12:** (3-Methyl-4-trifluoromethoxy-3H-benzothiazol-2-ylidene)-prop-2-ynyl-amine **12**

The title compound may be prepared from 2-imino-3-methyl-4-trifluoromethoxybenzothiazoline (prepared from 4-(trifluoromethoxy)-2-benzothiazolamine) by reacting it in toluene with propargylamine in the presence of p-TsOH at 125°C overnight.

**Example 13:** 2-(2-Prop-2-ynylimino-6-trifluoromethoxy-benzothiazole-3-yl)-1-p-tolyl-ethanone 13

Prop-2-ynyl-(6-trifluoromethoxy-benzothiazol-2-yl)-amine 5 (the compound of Ex. 4, 0.58 g, 2.14 mmol) was dissolved in acetonitrile (40 ml) and 2-bromo-4'-methylacetophenone (0.51 g, 2.14 mmol) was added, and the reaction mixture was refluxed for 48 h. The solvent was evaporated and the crude residue obtained was purified by chromatography to give 13 as a solid, 10 mp: 98-100°C (0.6 g, 6%).

<sup>1</sup>H NMR (DMSO<sub>d</sub><sub>6</sub>) δ: 7.97 (d, 2H, J = 8 Hz, COAr), 7.80 (d, 1H, J = 1 Hz, H-7), 7.40 (d, 1H, J = 8 Hz, COAr), 7.23 (dd, 1H, J = 8, 1 Hz, H-5), 7.17 (d, 1H, J = 8 Hz, H-4), 5.59 (s, 2H, CH<sub>2</sub>CO), 3.93 (d, 2H, J = 1.5 Hz, NCH<sub>2</sub>CC), 3.12 (t, 1H, J = 1.5 Hz, CCH), 2.41 (s, 3H, Ar-CH<sub>3</sub>). 15

<sup>13</sup>C NMR δ: 192.30 (CO), 158.21 (C-2), 145.60, 143.95, 140.83, 133.50, (4 x C, Ar), 130.30, 129.09, (4 x CH MeC<sub>6</sub>H<sub>4</sub>), 124.23 (Ar), 120.4 (CH, Ar), 120.0 (CF<sub>3</sub>O), 116.83, 110.84 (2 CH, Ar), 81.46, 72.37 (CH<sub>2</sub>CC), 50.47 (NCH<sub>2</sub>CO), 42.35 (NCH<sub>2</sub>), 21.64 20 (MeC<sub>6</sub>H<sub>4</sub>). 25

MS: 404 (M<sup>+</sup>, 43), 352 (7), 285 (75), 119 (100).

**Example 14:** Prop-2-ynyl-(3-prop-2-ynyl-6-trifluoromethoxy-3H-benzothiazol-2-ylidene)-amine 14

25 2-Imino-3-(2-propynyl)-6-trifluoromethoxy-benzothiazoline HBr (2.5 g, 7.08 mmol) was suspended in toluene (40 ml), and propargylamine (10 ml, 0.156 mol) and p-TsOH (0.444 g, 2.33 mmol) were added and the mixture was stirred at 150°C overnight. The solvent was evaporated and the dark residue was 30 purified by chromatography to give 14 as a white solid (0.15 g, 7%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ: 7.28 (d, 1H, J = 1.5 Hz, H-7), 7.18 (ddq, 1H, J = 9, 1.5, 1 Hz, H-5), 7.07 (d, 1H, J = 9 Hz, H-4), 4.80 (d, 35

2H,  $J = 2$  Hz,  $\text{NCH}_2$ ), 4.06 (d, 2H,  $J = 2$  Hz,  $\text{SCNCH}_2$ ), 2.29 (t, 1H,  $J = 2.5$  Hz, CCH), 2.27 (t, 2H,  $J = 2$  Hz, CCH).  
 $^{13}\text{C}$  NMR  $\delta$ : 157.14 (C-2), 143.64, 138.00, 123.52 (C-6, C-3a, C-7a), 120.2 ( $\text{CF}_3\text{O}$ ), 119.84, 115.84, 109.75 (3 CH, Ar), 80.44, 5 76.80 ( $\text{CH}_2\text{CC}$ ), 42.12 ( $\text{SCNCH}_2$ ), 32.76 ( $\text{NCH}_2$ ).  
MS (DCI,  $\text{CH}_4$ ): m/z 311 ( $\text{M}^+$ ).

**Example 15:** [3-(2-Methylsulfanyl-ethyl)-6-trifluoromethoxy-3H-benzothiazol-2-ylidene]-prop-2-ynyl-amine  
10 **15**

3-(2-Methylthio ethyl) -2-imino -6-trifluoromethoxy-benzothiazoline HCl (1g, 2.9 mmol) was suspended in toluene (25 ml), and propargylamine (4.5 ml, 4 g, 70 mmol) and p-TsOH (0.185 g, 1 mmol) were added and the mixture was stirred at 15 130-135°C under a nitrogen atmosphere for 24 h. The solvent was evaporated and the dark residue was purified by chromatography to give 15 as a viscous oil (0.1 g, 10%).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ : 7.28 (dd, 1H,  $J = 1, 1.5$  Hz, H-7), 7.11 (ddq, 1H,  $J = 9, 1.5, 1$  Hz, H-5), 7.07 (d, 1H,  $J = 9$  Hz, H-4), 4.18 20 (t, 2H,  $J = 7$  Hz,  $\text{NCH}_2$ ), 4.04 (d, 2H,  $J = 2$  Hz,  $\text{SCNCH}_2$ ), 2.82 (t, 2H,  $J = 7$  Hz,  $\text{CH}_2\text{SMe}$ ), 2.26 (t, 1H,  $J = 2$  Hz, CCH), 2.19 (s, 3H, SMe).  
 $^{13}\text{C}$  NMR  $\delta$ : 157.64 (C-2), 143.21, 138.79, 123.53 (C-6, C-3a, C-7a), 120.2 ( $\text{CF}_3\text{O}$ ), 119.75, 115.86, 109.04 (3 CH, Ar), 80.50, 25 70.92 ( $\text{CH}_2\text{CC}$ ), 43.39 ( $\text{SCNCH}_2$ ), 42.13 ( $\text{NCH}_2$ ), 30.60 ( $\text{CH}_2\text{SMe}$ ), 15.78 (SMe).  
MS (DCI, i-Bu) m/z : 347 ( $\text{M}^+$ ), 272 ( $\text{M}^+ - \text{C}_2\text{H}_4\text{SMe}$ ).

**Example 16:** 3-Methyl-2-(methyl-prop-2-ynyl-amino)-6-trifluoromethoxy-benzothiazol-3-ium iodide **16**  
30 (3-Methyl-6-trifluoromethoxy-3H-benzothiazol-2-ylidene)-prop-2-ynyl-amine (the compound of example 10, 120 mg, 0.42 mmol) was refluxed in MeI (3-4 ml) for 4 h. Then MEK (1 ml) was added and also additional amount of MeI (1-2 ml) and the

reaction was heated up to 75°C for additional 2h and then the mixture was stirred at rt for 24h. Excess MeI and solvent were evaporated to leave a brown-yellow residue which was treated with hexane, filtered and washed with hexane and ether to afford 30 mg (17%) of **16** as a brown solid. <sup>1</sup>H-NMR (DMSO<sub>6</sub>) δ 8.32 (s, 1 H, H-7), 7.97 (d, 1 H, J = 9 Hz, H-4), 7.72 (bd, 1 H, J = 9 Hz, H-5), 4.67 (d, 2 H, J = 1.5 Hz, CH<sub>2</sub>N), 4.01 (s, 3H, N<sup>+</sup>Me), 3.83 (bs, 1H, PgCH), 3.52 (s, 3H, NMe); <sup>13</sup>C (DMSO<sub>6</sub>) 173.27 (C-2), 145.83, 140.06, 124.72 (3 x C, C-3a, C-7a, C-6), 122.42, 117.04, 116.73 (3 x CH, Ar), 79.53, 76.42 (CH<sub>2</sub>CC), 46.61 (NCH<sub>2</sub>), 42.86 (N<sup>+</sup>Me), 38.26 (NMe); HRMS (FAB+) 286.0387 (M-MeI, 100).

**Example 17: Effect of 3a on MPP+ treated PC-12 cells.**

15 Pheochromocytoma PC-12 cells (at a density of 200,000 cells/well) were cultured for 10 days with 50 ng/ml NGF on 6-well culture dishes coated with 200 ug/ml rat tail type I collagen (BD Biosciences, Bedford, MA, USA). On the day of the experiment the morphological differentiation of the cells was 20 very advanced (typical network formation). In order to initiate the neurotoxic insult, cells were treated with 1000 μM of 1-methyl-4-phenylpyrdinium (MPP<sup>+</sup>) iodide salt from RBI chemicals (Natick, MA, USA) for 48 hours in the absence or presence of tested compounds, added to the culture 30 min. 25 prior to MPP<sup>+</sup> administration. MPP<sup>+</sup> has been shown to inhibit mitochondrial electron transport (complex I) in neurons and to induce a syndrome resembling Parkinson disease in mice and monkeys. At the cellular level, neuronal cell death is induced by several mechanisms including pathological 30 concentrations of intracellular calcium and free oxygen radicals. Therefore the positive control in this experiment was nimodipine at the concentration of 10μM (RBI chemicals, Natick, MA, USA) (a potent L-type calcium channel blocker). At the end of the experiment cell death was measured by assessing

Lactate dehydrogenase (LDH) activity in the medium. High medium LDH indicated increased neuronal death that promoted leakage of this cytoplasmic enzyme into the medium.

5 Measuring lactate dehydrogenase activity in the medium was performed using a Sigma Diagnostics LD-L reagent. LDH activity was spectrophotometrically monitored at 340 nm by following the rate of conversion of oxidized nicotinamide adenine dinucleotide (NAD<sup>+</sup>) to the reduced form of (NADH). Total LDH 10 of each culture (extracellular + intracellular) was obtained by measuring LDH in the medium after freezing and thawing of the cultures. Basal LDH release was measured in untreated cultures (no MPP<sup>+</sup>). The neurotoxic effect was calculated according to the formula: (LDH<sub>s</sub>-LDH<sub>b</sub>)/LDH<sub>t</sub> x 100. (s=sample; 15 b=basal; t=total). Each compound was tested in sixplicate.

Results are summarized in the table below. Without MPP<sup>+</sup> (control) cell death was very low, not exceeding 1.1% of total. After the MPP<sup>+</sup> insult, toxicity reached 49.7% (LDH 20 release as % of total). Pretreatment of the cultures with nimodipine (30 minutes before MPP<sup>+</sup>), reduced LDH release dramatically to a value of 3.6%, indicative of a strong neuroprotective effect. Pretreatment of cultures with 10  $\mu$ M 3a, reduced LDH release to a value of 10.9%, suggestive of a 25 strong neuroprotective effect.

Table 1: Percent of LDH Release

MPP+, 1000 $\mu$ M	Tested compound	Percent of total LDH release (mean $\pm$ S.E.M.)
-	-	1.1 $\pm$ 0.2
+	-	49.7 $\pm$ 5
+	Nimodipine, 10 $\mu$ M	3.6 $\pm$ 0.4
+	3a, 10 $\mu$ M	10.9 $\pm$ 2.3
+	4a, 10 $\mu$ M	25 $\pm$ 8.0

## Example 18

## 5 Effect of 3a on MPP+ toxicity in mice.

MPP+ is a neuro-toxin and its injection into the brain causes depletion of striatal dopamine. Male C57bl mice, weighing 24-25g were divided into 4 groups A-D receiving the following 10 treatments:

A: Oral administration of 0.25% Carboxymethyl cellulose (CMC, 0.1ml/mouse) and intracerebroventricular (ICV) injection of saline (10 $\mu$ l/mouse).

B. Oral administration of 5mg/kg 3a in 0.1ml CMC, and ICV injection of 10 $\mu$ l saline.

C. Oral administration of 0.1ml CMC, and ICV injection of 30 $\mu$ g MPP+ dissolved in 10 $\mu$ l saline.

D. Oral administration of 5mg/kg 3a in 0.1ml CMC, and ICV injection of 30 $\mu$ g MPP+ dissolved in 10 $\mu$ l saline.

25 3a/CMC or CMC alone were orally administered 30 minutes before and 2 hours after ICV injection. The injection was done according to Haley T.J and McCormick W.G (Brit.J. Pharmacol.,

1957, 12, 12) using ether anesthesia. Saline or MPP+/saline were injected during 1 second using a syringe that delivered the liquid at a rate of 0.6 ml/min. Two ICV injections were carried out with a 24 hour interval between them. Mice were 5 killed six days after the last injection and striata taken for dopamine and DOPAC determinations. Each striatum was weighed, homogenized in 0.1M Perchloric acid (0.6ml) containing 2mM sodium metabisulfite and 0.3mM EDTA. After centrifugation at 13000g for 7 minutes, the supernatant was taken for 10 catecholamine determination. Aliquots of 20 $\mu$ l were injected into the solvent stream of an HPLC apparatus equipped with a Microsorb column (packing 3 $\mu$ m, 4.6 mm diameter, 12.5 cm long). The mobile phase was composed of NaH<sub>2</sub>PO<sub>4</sub> 100 mM, octan-1-sulphonic acid 1.5 mM, disodium ethylenediaminetetraacetic acid 15 250  $\mu$ M, methanol 2.3%, acetonitrile 4% in grade deionized water, at a flow rate of 1.0 ml min<sup>-1</sup>. Dopamine and DOPAC were detected with an ESA Coulochem model 5014 detector (Bedford, MA, USA). Column eluates were initially oxidized by an ESA guard cell (model 5020) at +300 mV, then reduced at +60 mV at 20 detector 1 and measured at detector 2 at -250 mV.

Results are presented in the table below as concentrations of dopamine or DOPAC in pmol per mg striatal tissue. MPP+ caused a depletion of about 30% in striatal concentrations of 25 dopamine and DOPAC (Group C) and 3a reduced this depletion (Group D).

Table 2:

Group	MPP+	Drug	Dopamine Pmol/mg tissue +/-S.E.M.	DOPAC Pmol/mg tissue +/-S.E.M.
A (N=9)	-	CMC	64.7+/-8.7	4.0+/-0.3
B (N=9)	-	CMC+3a	78.2+/-4.3	4.8+/-0.4
C (N=10)	+	CMC	45.1 +/- 7.8	2.8+/-0.4
D (N=10)	+	CMC+3a	66.0 +/- 3.4	3.7 +/- 0.2

**Example 19****5 Activity of compounds of the invention in the Experimental Allergic Encephalomyelitis ("EAE") model of MS**

EAE is an accepted animal model of autoimmune disorder (Tisch et al. Proc. Natl. Acad. Sci. USA (1994) 91:437-438). EAE was 10 induced by injecting the encephalitogenic agent consisting of MSCH and commercial CFA containing *Mycobacterium tuberculosis* H37Ra to the foot-pads of the animals and pertussis toxin intravenously. - - - - -

**15 Administration of the test article:**

GA-DS in MSCH emulsion was injected in the four footpads. The other compounds were administered to the respective groups by oral gavage twice daily for 30 consecutive days starting from the day of induction until the termination of the study.

20

**Clinical signs**

Scoring of EAE clinical signs was initiated from Day 10 post-EAE induction and was continued daily for 20 days. The clinical signs were recorded on observation cards according to 25 a grading system described in the table below.

Table 3: Evaluation of the EAE clinical signs.

Score	Signs	Description
0	Normal behavior	No neurological signs.
1	Tail weakness	The mouse tail is limp and droops.
2	Hind legs weakness	Limb paresis, wobbly walk - when the mouse walks the hind legs are unsteady.
3	Hind legs paralysis	The mouse can't move its hind legs and it drags them when it walks.
4	Full paralysis	The mouse can't move its legs at all, it looks thinner and emaciated.
5	Death	

5 Calculation of the mortality rate

- The number of dead or moribund animals in each group were summed.

- The mortality rate was calculated as:

$$10 \quad \frac{\text{Number of dead or moribund mice in treated group}}{\text{Number of dead or moribund mice in control group}}$$

Calculation of the mean maximal score and percent inhibition

The mean maximal score (MMS) of each group was calculated as

$\sum$  maximal score of each mouse / number of mice in the group.

15 - The percent inhibition was calculated as

$$\text{Percent Inhibition} = 1 - \frac{(\text{MMS of treated group})}{\text{MMS of control group}} \times 100$$

Calculation of the mean group score and percent inhibition

The daily scores of each mouse in the test group was summed and the individual mean daily score (IMS) was calculated as  
 $IMS = \text{daily score of mouse} / \text{observation period (days)}$ .

5 The mean group score (GMS) will be calculated as

$\Sigma IMS \text{ of each mouse} / \text{number of mice in the group}$ .

The percent inhibition will be calculated as

10 Percent inhibition =  $1 - \frac{GMS \text{ of treated group}}{GMS \text{ of control group}} \times 100$

**Example 19a****Combination of compounds of the invention with GA**

15 The GA was weighed and diluted in sterilized phosphate buffered saline (PBS) and test compounds in 0.5% methyl-cellulose.

The results for treatment with compound 3 are summarized in  
20 Figures 1-A, 1-B and 1-C.

**Example 19b****Compounds of the invention (no GA)**

25 The results are summarized in the Table 4 and in Figures 2(a) and 2(b).


Other compounds which were made are tested and show activity comparable with the activity of the compounds  
30 which were tested.

Table 4. Inhibition of EAE clinical signs when dosed with 10 mg/kg twice daily.

Compound #	MMS % Inhibition	GMS % Inhibition	Mortality % Inhibition
3	73.5	87.5	100
9	48.8	57.6	50
10	34.1	37.5	40

What is claimed is:

1. A compound having the structure:



wherein

$R_1$  is present or absent, and when present is H,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkynyl,  $-(CH_2)_yS(CH_2)_xCH_3$ ,  $C_1-C_6$  aminoalkyl,  $C_1-C_6$  hydroxyalkyl or  $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$ ;

$R_2$  is H or  $C_1-C_4$  alkyl;

$R_3$  is H or  $C_1-C_4$  alkyl;

$R_4$  is present or absent, and when present is H,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkynyl,  $-(CH_2)_yS(CH_2)_xCH_3$ ,  $C_1-C_6$  aminoalkyl,  $C_1-C_6$  hydroxyalkyl or  $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$ ;

wherein n is an integer from 1-6;

wherein x is 0 or an integer from 1-5 and

y is an integer from 1-5, such that  $x+y < 6$ ;  
at least one of  $R_1$  or  $R_4$  is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and


the compound is charged when both  $R_1$  and  $R_4$  are present,

or a specific enantiomer thereof or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein at least one of  $R_1$  or  $R_4$  is  $-(CH_2)_nC(=O)(C_6H_4)(CH_2)R_2$ .

3. The compound of claim 1, wherein at least one of R<sub>1</sub> and R<sub>4</sub> is -(CH<sub>2</sub>)<sub>y</sub>S(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>.

4. The compound of claim 1, having the structure:



wherein

R<sub>1</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>2</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>3</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>4</sub> is present or absent, and when present is H or C<sub>1</sub>-C<sub>4</sub> alkyl;


at least one of R<sub>1</sub> or R<sub>4</sub> is present;

the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and


the compound is charged when both R<sub>1</sub> and R<sub>4</sub> are present,

or a specific enantiomer thereof or a pharmaceutically acceptable salt thereof.


5. The compound of claim 4, having the structure:



6. The compound of claim 4, having the structure:




7. The compound of claim 4, having the structure:




8. The compound of claim 4, 5, 6 or 7 wherein at least one of R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl.
9. The compound of claim 4 or 6, wherein R<sub>1</sub> is absent and R<sub>4</sub> is present.
10. The compound of claim 4, 5, 6 or 7 wherein the chiral carbon is in the R configuration.
11. The compound of claim 4, 5, 6 or 7 wherein the chiral carbon is in the S configuration.
12. The compound of claim 9, wherein R<sub>1</sub> is absent and R<sub>4</sub> is methyl.
13. The compound of claim 7, wherein R<sub>1</sub> is H or methyl;

$R_2$  is H or methyl;  
 $R_3$  is H or methyl,  
or a pharmaceutically acceptable salt thereof.


14. The pharmaceutically acceptable salt of the compound of any one of claims 1-13, wherein the salt is the chloride, mesylate, maleate, fumarate, tartarate, hydrochloride, hydrobromide, esylate, p-toluenesulfonate, benzoate, acetate, phosphate or sulfate salt.
15. The compound of claim 2 having the structure:




16. The compound of claim 1 having the structure:




17. The compound of claim 3 having the structure:




18. The compound of claim 3 having the structure:




19. The compound of claim 1 having the structure:



20. The compound of claim 2 having the structure:




21. The compound of claim 7, having the structure:




22. The hydrochloride salt of the compound of claim 21.

23. The compound of claim 7, having the structure:




24. The hydrochloride salt of the compound of claim 23.

25. The compound of claim 7, having the structure:




26. The hydrochloride salt of the compound of claim 25.

27. The compound of claim 7, having the structure:




28. The hydrochloride salt of the compound of claim 27.

29. The compound of claim 5, having the structure:




30. The hydrochloride salt of the compound of claim 29.

31. The compound of claim 6, having the structure:




32. The hydrochloride salt of the compound of claim 31.

33. The compound of claim 4, having the structure:



34. The compound of claim 4, having the structure:



35. A method for treating a subject afflicted with a neurologic disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, so as to thereby treat the neurologic disorder in the subject.

36. The method of claim 35, wherein the neurologic disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.

37. The method of claim 35, wherein the therapeutically effective amount is from about 1 to about 1000 mg/day.

38. A method for treating a subject afflicted with multiple sclerosis comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof so as to thereby treat multiple sclerosis in the subject.

39. The method of claim 38, further comprising administering to the subject a therapeutically effective amount of


levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.

40. The method of claim 38, wherein the therapeutically effective amount is from about 1 to about 1000 mg/day.
41. The method of claim 35 or 38 wherein the therapeutically effective amount of the compound is administered by injection, systemically, orally or nasally.
42. A method for destroying or inhibiting the proliferation of microbes or fungus which comprises contacting the microbes or fungus with a composition comprising the compound of claim 1 and an acceptable carrier.
43. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
44. The pharmaceutical composition of claim 43, further comprising a therapeutically effective amount of levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.
45. The pharmaceutical composition of claim 43, further comprising a therapeutically effective amount of glatiramer acetate.
46. A process for the manufacture of a pharmaceutical composition comprising admixing the compound of claim 1 with a pharmaceutically acceptable carrier.
47. A packaged pharmaceutical composition for treating a neurologic disorder in a subject comprising:
  - (a) the pharmaceutical composition of claim 43; and


(b) instructions for using the composition for treating the neurologic disorder in the subject.

48. A process of manufacturing the compound of claim 4 comprising the steps of:

(a) reacting




under suitable conditions with an amine exchanging agent in the presence of solvent to provide:




2

(b) treating 2 with a chlorinating agent to provide




3

(c) reacting 3 with



to provide



wherein


$\text{R}_1$  is present or absent, and when present is H or  $\text{C}_1\text{-C}_4$  alkyl;

$\text{R}_2$  is H or  $\text{C}_1\text{-C}_4$  alkyl;

$\text{R}_3$  is H or  $\text{C}_1\text{-C}_4$  alkyl; and


(d) optionally alkylating the product of step (c), wherein  $\text{R}_1$  is H, to provide the compound.

49. The process of claim 48, further comprising reacting the product of step (c), wherein  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  are each H, with 2-bromo-4'-methylacetophenone in a polar solvent in the presence of a base to produce a compound having the structure:




50. The process of claim 49, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

51. The process of claim 48, further comprising reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each H, with propargyl bromide in a polar solvent in the presence of a base to produce a compound having the structure:



52. The process of claim 51, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

53. The process of claim 48, further comprising reacting the product of step (c), wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each H, with 2-chloroethyl methylsulfide in a polar solvent in the presence of a base, to produce a compound having the structure:



54. The process of claim 53, wherein the polar solvent is acetonitrile and the base is potassium carbonate.


55. The process of claim 48, wherein the amine exchanging agent is a mixture of aqueous NH<sub>2</sub>NH<sub>2</sub> and hydrazinium sulfate in ethylene glycol.

56. The process of claim 55, wherein the chlorinating agent is  $\text{SOCl}_2$ .

57. The process of claim 56, wherein  $R_1$  is  $C_1\text{-}C_4$  alkyl and  $R_2$  and  $R_3$  are H.

58. The process of claim 48, wherein the alkylating agent in step (d) is methyl iodide or dimethyl sulfate.


59. A process of manufacturing a compound having the structure:



wherein

$\text{R}_1$  is  $C_1\text{-}C_4$  alkyl;  
 $\text{R}_2$  is H or  $C_1\text{-}C_4$  alkyl; and  
 $\text{R}_3$  is H or  $C_1\text{-}C_4$  alkyl,


comprising reacting a compound having the structure:



with  $\text{R}_1\text{X}$  in a polar solvent in the presence of a base, wherein X is a halogen atom, to produce the compound.

60. The process of claim 59, wherein the polar solvent is acetonitrile and the base is potassium carbonate.

61. A process of manufacturing a compound having the structure:




wherein

$R_2$  is H or  $C_1-C_4$  alkyl; and


$R_3$  is H or  $C_1-C_4$  alkyl,

comprising,


a) reacting



under suitable conditions with a methylating agent, in the presence or absence of solvent to provide:




b) reacting the product of step a) with



in the presence of p-toluenesulfonic acid to provide the compound.


62. The process of claim 61, wherein the product of step (b) is further alkylated with an alkylating agent to provide a compound having the structure:



63. The process of claim 61, wherein the methylating agent in step (a) is methyliodide or dimethyl sulfate.


64. The process of claim 62 wherein the methylating agent is methyliodide.

65. A process of manufacturing the compound of claim 19 comprising reacting a compound having the structure:




with propargylamine and p-TsOH in toluene to produce the compound.

66. A process of manufacturing the compound of claim 18 comprising reacting a compound having the structure:




with propargylamine and p-TsOH in toluene to produce the compound.

67. A process of manufacturing the compound of claim 20 comprising reacting a compound having the structure:



with





in a polar solvent to produce the compound.

68. The process of claim 67, wherein the polar solvent is acetonitrile.


69. Use of the compound of any one of claims 1-34 for manufacturing a medicament useful for treating a neurologic disorder in a subject.

70. The use of claim 69, wherein the neurologic disorder is Parkinson's Disease, Alzheimer's Disease, amyotrophic lateral sclerosis, stroke, a neuromuscular disorder, schizophrenia, cerebral infarction, head trauma, glaucoma, facialis or Huntington's Disease.
71. Use of the compound of any one of claims 1-34 for manufacturing a medicament useful for treating multiple sclerosis in a subject.
72. The use of claim 71, wherein the medicament further comprises levodopa, glatiramer acetate, interferon beta-1b, interferon beta-1a, steroids or Mitoxantrone.
73. Use of the compound of any one of claims 1-34 for manufacturing a medicament in a package having instructions for administration of the medicament to treat a neurologic disorder in a subject.



1/3

**FIGURE 1-A****FIGURE 1-B**

2/3

**FIGURE 1-C**

3/3

**FIGURE 2****(A)****Inhibition of EAE in CSJL/F1 Mice****(B)****Inhibition of EAE in Lewis Rats**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**